Abstract
Inflammation and coagulation are two systems playing pivotal roles in host defense. As phylogenetically old responses, there is extensive crosstalk between inflammation and coagulation in assuring adequate immune response against injurious stimuli. The crosstalk between activated coagulation and inflammatory mediators is highlighted. Inflammation activates coagulation and coagulation modulates the inflammatory activity in many ways. The contributing pathways are reviewed. Understanding the mechanisms involved in the crosstalk between inflammation and coagulation may yield new therapeutic strategies for human diseases. Immune cells are important in the initiation of coagulation pathways, while different inflammatory mediators could alter haemostasis. Vice versa, coagulation proteases have significant immuno-modulatory effects. The mechanisms controlling the interaction between inflammation and coagulation are described. Fibrinolysis is significantly involved in the inflammation-coagulation balance. Protease-activated receptors also play an important role in the interaction between coagulation and inflammation. Elucidating the mechanisms of crosstalk between coagulation and inflammation increases our understanding of the pathological and pathophysiological events of severe clinical diseases, and may yield new therapeutic targets in the near future.

Keywords
coagulation, inflammation, innate immunity, fibrinolysis,

Cite this paper
Kollarou Anna, The interaction of inflammation and coagulation systems , SCIREA Journal of Biology. Volume 1, Issue 2, December 2016 | PP. 93-105.

References

[ 1 ]	Choi G, Schultz MJ, Levi M, van der Poll T. The relationship between inflammation and the coagulation system. Swiss Med Wkly. 2006; 136(9-10): 139-144.
[ 2 ]	Degen JL, Bugge TH, Goguen JD. Fibrin and fibrinolysis in infection and host defense. J Thromb Haemost. 2007; 5(Suppl 1): 24–31.
[ 3 ]	Sun H. The interaction between pathogens and the host coagulation system. Physiology (Bethesda) 2006; 21(4): 281–288.
[ 4 ]	Furie B, Furie BC. Thrombus formation in vivo. J Clin Invest. 2005; 115(12): 3355–3362.
[ 5 ]	Mackman N, Tilley RE, Key NS. Role of the extrinsic pathway of blood coagulation in hemostasis and thrombosis. Arterioscler Thromb Vasc Biol. 2007; 27(8): 1687–1693.
[ 6 ]	Galal AZ, Shoeib SA, El Barbary HS, Abu-Sabala WR. Clinical aspects of the haemostasis-inflammation interface. Menoufia Med J. 2015; 28: 282–288.
[ 7 ]	Andersson E. Crosstalk between inflammation and coagulation in acute pancreatitis. Doctoral thesis. 2010; Bulletin No. 138 from the Department of Surgery, Clinical Sciences Lund University, Sweden 80 p.
[ 8 ]	Coughlin SR. Protease-activated receptors in hemostasis, thrombosis and vascular biology. J Thromb Haemost. 2005; 3: 1800–1814.
[ 9 ]	Esmon CT. Inflammation and the activated protein C anticoagulant pathway. Semin Thromb Hemost. 2006; 32(suppl 1): 49-60.
[ 10 ]	Esmon CT, Xu J, Lupu F. Innate immunity and coagulation. J Thromb Haemost. 2011; 9(Suppl 1): 182–188.
[ 11 ]	d’Angelo A, Vigano d’Angelo S. Protein S deficiency. Haematologica. 2008; 93(4): 498–501.
[ 12 ]	Shibamiya A, Hersemeyer K, Wöll TS, Sedding D, Daniel J-M, Bauer S et al. A key role for Toll-like receptor-3 in disrupting the hemostasis balance on endothelial cells. Blood. 2009; 113(3): 714–722.
[ 13 ]	Jeon H, Kim JH, Kim JH, Lee WH, Lee MS, Suk K. Lay AJ. Plasminogen activator inhibitor type 1 regulates microglial motility and phagocytic activity. J Neuroinflammation. 2012; 22 p.
[ 14 ]	Kerschen E, Hernandez I, Zogg M, Jia S, Hessner MJ, Fernández JA et al. Activated protein C targets CD8+ dendritic cells to reduce the mortality of endotoxemia in mice. J Clin Invest. 2010; 120(9): 3167–3178.
[ 15 ]	Levi M, Keller TT, van Gorp E, ten Cate H. Infection and inflammation and the coagulation system. Cardiovasc Res. 2003; 60: 26–39.
[ 16 ]	Opal SM, Esmon CT. Bench-to-bedside review: functional relationships between coagulation and the innate immune response and their respective roles in the pathogenesis of sepsis. Crit Care. 2003; 7(1): 23–38.
[ 17 ]	Danese S, Vetrano S, Zhang L, Poplis VA, Castellino FJ. The protein C pathway in tissue inflammation and injury: pathogenic role and therapeutic implications. Blood. 2010; 115(6): 1121–1130.
[ 18 ]	Tienken RS. Niacin in dairy cow rations: Investigations on the bioavailability of niacin and its interactions with dietary energy density on the health and performance of dairy cows. Doctoral dissertation University of Veterinary Medicine Hannover. 2016.
[ 19 ]	Kollarou A. New coumarin derivatives synthesis and study of their biological effectiveness. Diploma Thesis, Democritus University of Thrace, Dept. of Molecular Biology and Genetics. 2009; 63 p.
[ 20 ]	Honda K, Wada H, Nakamura M, Nakamoto K, Inui T, Sada M, Koide T, Takata S, Yokoyama T, Saraya T, Kurai D, Ishii H, Goto H, Takizawa H. IL-17A synergistically stimulates TNF-α-induced IL-8 production in human airway epithelial cells: A potential role in amplifying airway inflammation. Exp Lung Res. 2016; 42(4): 205-216.
[ 21 ]	Amara U, Flierl MA, Rittirsch D, Klos A, Chen H, Acker B et al. Molecular inter-communication between the complement and coagulation systems. J Immunol. 2010; 185(9): 5628-5636.
[ 22 ]	Bernardo A, Ball C, Nolasco L, Moake JF, Dong J. Effects of inflammatory cytokines on the release and cleavage of the endothelial cell-derived ultra-large von Willebrand factor multimers under flow. Blood. 2004; 104(1): 100–106.
[ 23 ]	Lipinski S, Bremer L, Lammers T, Thieme F, Schreiber S, Rosenstiel P. Coagulation and inflammation. Molecular insights and diagnostic implications. Hämostaseologie. 2011; 31(2): 94-104.
[ 24 ]	Esmon CT. Regulation of blood coagulation. Biochim Biophys Acta. 2000; 1477(1-2): 349–360.
[ 25 ]	Jankun J, Aleem AM, Selman SH, Skrzypczak-Jankun E, Lysiak-Szydlowska W, Grafos N, Fryer HJL, Greenfield RS. Highly stable plasminogen activator inhibitor type one (VLHL PAI-1) protects fibrin clots from tissue plasminogen activator-mediated fibrinolysis. Int J Mol Med. 2007; 20(5): 683-687.
[ 26 ]	Levi M, Lowenberg E, Meijers JC. Recombinant anticoagulant factors for adjunctive treatment of sepsis. Semin Thromb Hemost. 2010; 36(5): 550–557.
[ 27 ]	Fisher Jr CJ, Yan SB. Protein C levels as a prognostic indicator of outcome in sepsis and related diseases. Crit Care Med. 2000; 28(9 Suppl): S49–S56.
[ 28 ]	Levi M., van der Poll T, ten Cate H. Tissue factor in infection and severe inflammation. Semin Thromb Hemost. 2006; 32(1): 33–39.
[ 29 ]	Demetz G, Ott I. The interface between inflammation and coagulation in cardiovascular disease. Int J Inflam. 2012; 1-8.
[ 30 ]	Petäjä J. Inflammation and coagulation. An overview. Thromb Res. 2011; 127(Suppl 2): S34–S37.
[ 31 ]	Franco RF, de Jonge E, Dekkers PE, Timmerman JJ, Spek CA, van Deventer SJ et al. The in vivo kinetics of tissue factor messenger RNA expression during human endotoxemia: Relationship with activation of coagulation. Blood. 2000; 96(2): 554–559.
[ 32 ]	Østerud B, Bjørklid E. Sources of tissue factor. Semin Thromb Hemost. 2006; 32(1): 11–23.
[ 33 ]	Schouten M, Wiersinga WJ, Levi M, van der Poll T. Inflammation, endothelium, and coagulation in sepsis. J Leukoc Biol. 2008; 83(3): 536–545.
[ 34 ]	Blasi F, Carmeliet P. uPAR: a versatile signaling orchestrator. Nature Review Molecular Cellular Biology. 2002; 3(12): 932–943.
[ 35 ]	Szaba FM, Smiley ST. Roles for thrombin and fibrin(ogen) in cytokine/chemokine production and macrophage adhesion in vivo. Blood. 2002; 99(3): 1053–1059.
[ 36 ]	Coughlin SR. Thrombin signalling and protease-activated receptors. Nature. 2000; 407(6801): 258–264.